All In Biotech

Drug Trial Radar · NCT04998201

Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia

A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Mixed Dyslipidemia

Last checked: Nov 19, 2026Latest source record: Apr 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 353 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

353

Actual

Start

Sep 28, 2021

Primary completion

Feb 10, 2023

Study completion Aug 14, 2023

Sponsor

Lead sponsor
Arrowhead PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Aug 10, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Participants who have met all protocol eligibility criteria will be randomly assigned to treatment (ARO-APOC3 or placebo) in a double-blind fashion and will be evaluated for safety and efficacy over 48 weeks. Participants will be counseled to remain on a specified diet throughout the study, as recommended by the Investigator in accordance with local standards of care. After week 48, participants will be eligible and invited to consent and continue in an open-label extension study. All placebo participants who opt to continue will switch to active drug (ARO-APOC3) during the extension study.

Conditions

  • Mixed Dyslipidemia

Interventions

  • ARO-APOC3Drug

    ARO-APOC3 Injection

  • PlaceboDrug

    Sterile Normal Saline (0.9% NaCl)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline at Week 24 in Fasting TGTime frame: Baseline, Week 24

Locations

30 sites in 6 countries. Site status is shown where the registry gives one.

  • Research Site 3

    Beverly Hills, California

  • Research Site 8

    Northridge, California

  • Research Site 2

    Boca Raton, Florida

  • Research Site 1

    Fort Lauderdale, Florida

  • Research Site 14

    Miami Springs, Florida

  • Research Site 5

    Pembroke Pines, Florida

  • Research Site 18

    Dunwoody, Georgia

  • Research Site 31

    Las Vegas, Nevada

  • Research Site 17

    New Windsor, New York

  • Research Site 12

    Dayton, Ohio

  • Research Site 4

    Franklin, Ohio

  • Research Site 7

    Greenville, South Carolina

  • Research Site 6

    Houston, Texas

  • Research Site 32

    Houston, Texas

  • Research Site 13

    San Antonio, Texas

  • Research Site 30

    Morayfield, Queensland, Australia

  • Research Site 29

    Adelaide, South Australia, Australia

  • Research Site 19

    Clayton, Victoria, Australia

  • Research Site 27

    Joondalup, Western Australia, Australia

  • Research Site 15

    Concord, Ontario, Canada

  • Research Site 10

    Montreal, Quebec, Canada

  • Research Site 20

    Balatonfüred, Hungary

  • Research Site 21

    Debrecen, Hungary

  • Research Site 22

    Nyíregyháza, Hungary

  • Research Site 11

    Auckland, New Zealand

  • Research Site 16

    Christchurch, New Zealand

  • Research Site 28

    Lodz, Poland

  • Research Site 24

    Lodz, Poland

  • Research Site 25

    Poznan, Poland

  • Research Site 26

    Rzeszów, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.